STOCK TITAN

Xebra Brands Announces Warrant Extension

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Neutral)
Tags

Xebra Brands (CSE:XBRA)(OTCQB:XBRAF)(FSE:9YC0) has announced an extension of the expiry date for 13,311,731 outstanding warrants. The 2023 Warrants, with an exercise price of $0.10, were initially set to expire on September 6, 2024, then extended to December 31, 2024, and are now being further extended to June 30, 2025, subject to Canadian Securities Exchange approval.

According to Interim CEO Rodrigo Gallardo, several warrant holders have shown interest in exercising their warrants, and this extension will provide time for the process. The funds from these warrants are intended to provide additional capital to support growth and strengthen the company's first-mover advantage in Mexico.

Xebra Brands (CSE:XBRA)(OTCQB:XBRAF)(FSE:9YC0) ha annunciato un'estensione della data di scadenza per 13.311.731 warrant in circolazione. I warrant 2023, con un prezzo di esercizio di $0,10, erano inizialmente previsti per scadere il 6 settembre 2024, poi prorogati al 31 dicembre 2024, e ora vengono ulteriormente estesi al 30 giugno 2025, soggetto ad approvazione della Canadian Securities Exchange.

Secondo l'Amministratore Delegato ad interim Rodrigo Gallardo, diversi detentori di warrant hanno mostrato interesse nell'esercitare i loro warrant, e questa estensione fornirà il tempo necessario per il processo. I fondi derivanti da questi warrant sono destinati a fornire ulteriore capitale per sostenere la crescita e rafforzare il vantaggio competitivo dell'azienda in Messico.

Xebra Brands (CSE:XBRA)(OTCQB:XBRAF)(FSE:9YC0) ha anunciado una extensión de la fecha de vencimiento para 13,311,731 opciones en circulación. Las opciones 2023, con un precio de ejercicio de $0.10, estaban inicialmente programadas para vencer el 6 de septiembre de 2024, luego se extendieron al 31 de diciembre de 2024, y ahora se están extendiendo aún más hasta el 30 de junio de 2025, sujeto a la aprobación de la Canadian Securities Exchange.

Según el CEO interino Rodrigo Gallardo, varios tenedores de opciones han mostrado interés en ejercer sus opciones, y esta extensión proporcionará tiempo para el proceso. Los fondos de estas opciones están destinados a proporcionar capital adicional para apoyar el crecimiento y fortalecer la ventaja inicial de la empresa en México.

Xebra Brands (CSE:XBRA)(OTCQB:XBRAF)(FSE:9YC0)가 13,311,731개의 유효한 워런트의 만료일 연장을 발표했습니다. 2023년 워런트는 $0.10의 행사 가격으로, 처음에는 2024년 9월 6일로 만료될 예정이었으며, 이후 2024년 12월 31일로 연장되었고, 지금은 2025년 6월 30일로 추가 연장되었으며, 이는 캐나다 증권 거래소의 승인을 조건으로 합니다.

임시 CEO인 로드리고 갈라도에 따르면, 여러 워런트 보유자들이 그들의 워런트를 행사하는 데 관심을 보였으며, 이번 연장이 그 과정에 시간을 줄 것입니다. 이 워런트에서 발생한 자금은 추가 자본을 제공하여 성장을 지원하고 멕시코에서의 기업의 선도적인 이점을 강화하기 위한 것입니다.

Xebra Brands (CSE:XBRA)(OTCQB:XBRAF)(FSE:9YC0) a annoncé une prolongation de la date d'expiration pour 13 311 731 bons de souscription en circulation. Les bons de souscription 2023, avec un prix d'exercice de 0,10 $, devaient initialement expirer le 6 septembre 2024, ont ensuite été prolongés jusqu'au 31 décembre 2024, et sont maintenant prolongés jusqu'au 30 juin 2025, sous réserve de l'approbation de la Canadian Securities Exchange.

Selon le PDG par intérim Rodrigo Gallardo, plusieurs détenteurs de bons de souscription ont manifesté leur intérêt pour exercer leurs bons, et cette prolongation offrira le temps nécessaire pour le processus. Les fonds provenant de ces bons de souscription sont destinés à fournir un capital supplémentaire pour soutenir la croissance et renforcer l'avantage compétitif de l'entreprise au Mexique.

Xebra Brands (CSE:XBRA)(OTCQB:XBRAF)(FSE:9YC0) hat eine Verlängerung des Fälligkeitsdatums für 13.311.731 ausstehende Warrants angekündigt. Die 2023 Warrants mit einem Ausübungspreis von 0,10 $ sollten ursprünglich am 6. September 2024 ablaufen, wurden dann auf den 31. Dezember 2024 verlängert und werden nun bis zum 30. Juni 2025 weiter verlängert, vorbehaltlich der Genehmigung durch die Canadian Securities Exchange.

Laut dem Interim-CEO Rodrigo Gallardo haben mehrere Warrant-Inhaber Interesse bekundet, ihre Warrants auszuüben, und diese Verlängerung wird Zeit für den Prozess bieten. Die Gelder aus diesen Warrants sind dazu gedacht, zusätzliches Kapital bereitzustellen, um das Wachstum zu unterstützen und den Wettbewerbsvorteil des Unternehmens in Mexiko zu stärken.

Positive
  • Potential incoming capital through warrant exercises at $0.10 per share
  • Interest from warrant holders in exercising their warrants
  • Strategic position as first-mover in Mexican market
Negative
  • Need for extension suggests possible challenges in warrant execution within original timeframe
  • Multiple warrant extensions may indicate capital raising difficulties

VANCOUVER, BC / ACCESSWIRE / December 11, 2024 / Xebra Brands Ltd. ("Xebra" or the "Company") (CSE:XBRA)(OTCQB:XBRAF)(FSE:9YC0), a cannabis company, is pleased to announce that, subject to the approval of the Canadian Securities Exchange, it is extending the expiry date of an aggregate of 13,311,731 outstanding warrants (the "2023 Warrants").

The exercise price of the 2023 Warrants is $0.10. Initially set to expire on September 6, 2024, the original expiration date was previously extended to December 31, 2024. The Company has decided to further extend the expiration date of the 2023 Warrants to June 30, 2025. All other terms and conditions of the 2023 Warrants remain unchanged.

"Several of Xebra's warrant holders have expressed interest in exercising their warrants, and this extension provides the necessary time to facilitate that process. The funds from these warrants will provide additional capital to support our growth and strengthen our first-mover advantage in Mexico," said Rodrigo Gallardo, Interim CEO, President and Director.

ON BEHALF OF THE BOARD:

Rodrigo Gallardo
Interim CEO, President and Director

For more information contact:

ir@xebrabrands.com

Certain information contained in this press release constitutes forward-looking statements under applicable securities laws. Any statements that are not statements of historical fact may be deemed to be forward-looking statements, these include, without limitation, statements regarding Xebra Brands Ltd.'s expectations in respect of its ability to successfully execute its business plan or business model; its ability to enter into and execute partnerships or joint venture opportunities on acceptable terms; statements regarding expected benefits of partnerships and supply agreements, its ability to provide economic, environmental, social, or any benefits of any type in the communities it operates in or may operate it in the future; its ability to be a first mover in a country, or to obtain or retain government licenses, permits or authorizations in general, or specifically in Mexico, Canada, or elsewhere, including cannabis authorizations from the Mexican Health Regulatory Agency (COFEPRIS); its ability to satisfy the conditions of authorizations granted by COFEPRIS; its ability to successfully apply for, obtain and retain trademarks and other intellectual property in any jurisdiction; its ability to be cost competitive; its ability to commercialize, cultivate, grow, or process hemp or cannabis in Mexico, Canada, or elsewhere and related plans and timing; its ability to manufacture, commercialize or sell cannabis-infused beverages, wellness products, or other products in Mexico, Canada, or elsewhere, and its related plans and claims, including market interest and availability; its ability to create wellness products that have a therapeutic effect or benefit; plans for future growth and the direction of the business; plans to increase product volumes, the capacity of existing facilities, supplies from third party growers and contractors; expected growth of the cannabis industry generally; management's expectations, beliefs and assumptions in general, including manufacturing costs, production activity and market potential in Mexico or any jurisdiction; events or developments that Xebra expects to take place in the future; general economic conditions; and other risk factors described in the MD&A of the Company for the period ended November 30, 2023. All statements, other than statements of historical facts, are forward-looking information and statements. The words "aim", "believe", "expect", "anticipate", "contemplate", "target", "intends", "continue", "plans", "budget", "estimate", "may", "will", and similar expressions identify forward-looking information and statements. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by Xebra as of the dates of such statements, are inherently subject to significant business, economic and competitive uncertainties and contingencies. Known and unknown factors could cause actual results to differ materially from those projected in the forward-looking statements. Such factors include, but are not limited to, the inability of Xebra to retain the authorizations granted by COFEPRIS, the inability to successfully complete financings on terms acceptable to Xebra or at all, the inability to generate sufficient revenues or to raise sufficient funds to carry out its business plan; changes in government legislation, taxation, controls, regulations and political or economic developments in various countries; risks associated with agriculture and cultivation activities generally, including inclement weather, access to supply of seeds, poor crop yields, and spoilage; compliance with import and export laws of various countries; significant fluctuations in cannabis prices and transportation costs; the risk of obtaining necessary licenses and permits; inability to identify, negotiate and complete potential acquisitions, dispositions or joint ventures for any reason; the ability to retain key employees; dependence on third parties for services and supplies; non-performance by contractual counter-parties; general economic conditions; the continued growth in global demand for cannabis products and the continued increase in jurisdictions legalizing cannabis; and the timely receipt of regulatory approvals for license applications on terms satisfactory to Xebra. In addition, there is no assurance Xebra will: be a low-cost producer or exporter; obtain a dominant market position in any jurisdiction; have products that will be unique. The foregoing list is not exhaustive and Xebra undertakes no obligation to update or revise any of the foregoing except as required by law. Many of these uncertainties and contingencies could affect Xebra's actual performance and cause its actual performance to differ materially from what has been expressed or implied in any forward-looking statements made by, or on behalf of, Xebra. Readers are cautioned that forward-looking statements are not guarantees of future performance and readers should not place undue reliance on such forward-looking statements. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those set out in such statements.

SOURCE: Xebra Brands Ltd



View the original press release on accesswire.com

FAQ

How many warrants did Xebra Brands (XBRAF) extend in December 2024?

Xebra Brands extended 13,311,731 outstanding warrants.

What is the new expiration date for Xebra Brands' 2023 Warrants?

The 2023 Warrants have been extended to June 30, 2025.

What is the exercise price of Xebra Brands' extended warrants?

The exercise price of the 2023 Warrants is $0.10.

How will Xebra Brands (XBRAF) use the funds from warrant exercises?

The funds will be used to provide additional capital to support growth and strengthen the company's first-mover advantage in Mexico.

How many times has Xebra Brands extended these warrants?

These warrants have been extended twice: first from September 6, 2024 to December 31, 2024, and then to June 30, 2025.

XEBRA BRANDS LTD

OTC:XBRAF

XBRAF Rankings

XBRAF Latest News

XBRAF Stock Data

2.14M
54.35M
27.22%
Drug Manufacturers - Specialty & Generic
Healthcare
Link
United States of America
Vancouver